nivolumab,lucitanib
bms,servier,clovis oncology
['nivo', 'gyn', 'lucitanib', 'nivolumab', 'biomarker']
the combination of #immunotherapy and #antiangiogenics has clear rationale. phase 1 trial of lucitanib and nivolumab demonstrated clinical activity in #gynecologiccancers but it is clear that biomarkers are needed for selection. #gyncsm #asco22 
Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. #JCO social media editor. Opinions=mine.
https://t.co/QLXLDKSThc